Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Not yet recruiting 3Completed 3Terminated 2Active not recruiting 2

Sponsor Class

OTHER 48INDUSTRY 31NETWORK 8NIH 3OTHER_GOV 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Classical hematology 1

Conditions

Multiple Myeloma 3Anemia 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NIH × carfilzomib × Clear all
NCT01572480 2026-03-10

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
55 enrolled 17 charts
Plasma cell

Multiple Myeloma

NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Classical hematologyPlasma cell

Anemia, Multiple Myeloma

NCT01402284 2021-03-02

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
45 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡